看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。- l' o" r9 h$ o* n. p
& H6 d0 t& Q1 {/ X E6 v% S
4 M, C+ S) R/ X+ m# s3 iCurrently available feasibility data for possible combination strategies. : e" U: s2 o. h' O0 y% e5 o3 Z
————————————————————————————————
9 K, p6 \5 k. g3 W' A+ a' C7 QCombination Feasibility according to preliminary data
! L) c1 y* N6 M K/ G! J Y; \——————————————————————————————————
4 `$ ^, ^% j$ I" y- I7 `Bevacizumab + sorafenib Yes, reduced dose + k, t3 {4 u+ ]5 S
Bevacizumab + sunitinib† No # j5 N1 O1 T% C# U) Y4 v$ O- W) }
Bevacizumab + temsirolimus Yes
2 ]1 c1 b2 m6 V b% r5 J% lBevacizumab + everolimus Yes 4 E" A! { y1 C' A9 V1 ]7 |: N
Sorafenib + sunitinib ?
8 v4 A. k, e+ _. ?; [Sorafenib + temsirolimus Yes, reduced dose + y4 C) I4 R, X) m. g
Sorafenib + everolimus Yes, reduced dose
) p: H! Q1 n$ }Sunitinib + temsirolimus† No
" H6 Z4 b8 |5 g: F; pSunitinib + everolimus ? 5 y) u3 a# z4 y' w+ f6 ~- B
Temsirolimus + everolimus ?
( ^: f) S+ ~! B3 W7 u7 ^0 ]————————————————————% _+ t X+ }& }' a& e v0 @( n( r
†Led to US FDA warning.. {2 ~6 u# E, b" G0 y' n
?: As yet unattempted combination.
/ N; J6 s) |4 {/ _. S9 M0 T |